Advances in Immunotherapy of Biomarkers for Non-small Cell Lung Cancer Based on Radiomics
DOI:
https://doi.org/10.62051/nscfth04Keywords:
Radiomics; Non-small cell lung cancer; Biomarkers; Immunotherapy.Abstract
With the development of immunotherapy for non-small cell lung cancer (NSCLC), it has become increasingly crucial to evaluate the efficacy of immunotherapy and screen for the beneficiary population. However, how to use radiomics to screen suitable immune checkpoint markers and analyze immunotherapy prognosis is still lacking in-depth research. In this study, the basic concepts of radiomics were explored and biomarkers were analyzed in combination with computed tomography (CT) and positron emission tomography (PET/CT). Considering programmed death ligand 1 (PD-L1) expression status and tumor mutational load in patients receiving immunotherapeutic treatment, We developed a deep learning model that is non-invasive and analyzed relevant studies to screen for suitable biomarkers. In addition, we analyzed the effect of tumor immune microenvironment profile (TIME profile) on immune checkpoint inhibitors (ICIs) response, providing valuable parameters for cell cycle-dependent kinase inhibitor (CKI) therapy in advanced patients, and investigated the risk assessment for pneumonia linked to immune checkpoint inhibitors (ICIP). All things considered, radiomics can help support clinically tailored treatment and is very useful in forecasting the effectiveness and side effects of immunotherapy in patients with NSCLC.
Downloads
References
[1] Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Zheng, J., Xu, S., Wang, G. & Shi, Y. Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer. Front Immunol,2024, 15: 1434171.
[3] Yang, Y. et al. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. Am J Transl Res, 2021, 13(2): 743-756.
[4] Hou, Y., Zhang, T. & Wang, H. Advancements in Radiomics for Immunotherapy of Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi, 2024, 27(8): 637-633.
[5] Shi, L. et al. Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer. Technol Cancer Res Treat, 2018, 17: 1533033818782788.
[6] Vaidya, P. et al. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. J Immunother Cancer, 2020, 8(2).
[7] Li, Y. et al. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition. Oncoimmunology, 2024, 13(1): 2312628.
[8] Wang, J. et al. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer. BMC Med Imaging, 2024, 24(1): 45.
[9] Yang, J. et al. Establishing a predictive model for tumor mutation burden status based on CT radiomics and clinical features of non-small cell lung cancer patients. Transl Lung Cancer Res, 2023, 12(4): 808-823.
[10] Kaira, K., Kuji, I. & Kagamu, H. Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. Cancer Imaging, 2021, 21(1): 11.
[11] Aydos, U. et al. Texture features of primary tumor on (18)F-FDG PET images in non-small cell lung cancer: The relationship between imaging and histopathological parameters. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2021.
[12] Mu, W. et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun, 2020, 11(1): 5228.
[13] Sako, C. et al. Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer. JCO Clin Cancer Inform, 2024, 8: e2400133.
[14] Wen, Q., Yang, Z., Dai, H., Feng, A. & Li, Q. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Front Oncol, 2021, 11: 620246.
[15] Tong, H. et al. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. Front Immunol, 2022, 13: 859323.
[16] Zhao, X. et al. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [(18)F]FDG PET/CT radiomics. EJNMMI Res, 2023, 13(1): 4.
[17] Tutino, F. et al. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: interobserver agreement and reproducibility across software platforms. Nucl Med Commun, 2021, 42(3): 284-291.
[18] Ventura, D. et al. Radiomics of Tumor Heterogeneity in (18)F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. Cancers (Basel), 2023,15(8).
[19] Shu, Y. et al. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis. Front Immunol, 2023, 14:1251645.
[20] Shroff, G. S. et al. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer. Radiographics, 2022, 42(7): 1956-1974.
[21] Peng, L. et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother, 2020, 69(9): 1813-1822.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
